On the expanding terminology in the GPCR field: The meaning of receptor mosaics and receptor heteromers by Agnati, Luigi F. et al.
On the expanding terminology in the GPCR field: the meaning of
receptor mosaics and receptor heteromers
Luigi F. Agnati1, Diego Guidolin2, Jean Pierre Vilardaga3,4, Francisco Ciruela5, and Kjell
Fuxe6
1IRCCS San Camillo, Lido Venezia, Italy
2Department of Human Anatomy and Physiology, University of Padova, Padova, Italy
3Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh,
Pennsylvania, USA
4Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts, USA
5Unitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de
Medicina, IDIBELL-Universitat de Barcelona, Barcelona, Spain
6Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
Abstract
The oligomerization of G protein-coupled receptors (GPCRs) is a fact that deserves further
attention as increases both the complexity and diversity of the receptor-mediated signal
transduction, thus enriching the cell signaling. Consequently, in the present review we tackle
among others the problems concerning the terminology used to describe aspects surrounding the
GPCRs oligomerization phenomenon. Therefore, the theoretical implications of the GPCR
oligomerization will be briefly discussed together with possible implications of this phenomenon
especially for new strategies in drug development.
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Introduction
In the eighties, our group gave strong experimental indications that G protein-coupled
receptors (GPCRs) could interact, directly or via accessory proteins, at the plasma
membrane level (1–3). The hypothesis was also put forward that GPCRs could form high-
order oligomers (4–6). A fundamental consequence of this view was that not only the
recognition/decoding processes at GPCRs, and hence the information handling at neural
network level, but also the conventional design of drugs acting on GPCRs had to be
revisited. Thus, it was no longer possible to describe signal transduction as the result of the
binding of the chemical signal to its receptor, but rather as the result of a filtering/integration
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of chemical signals in receptor assemblies. In addition, the drug design could no longer be
built mainly on the activation or blockade of a single receptor at a usually well-defined
ligand-binding site (orthosteric binding site).
GPCRs are currently thought to form and signal as monomers and/or dimers; whether they
can form high-order structures (now called higher-order oligomers) is a topic of an intense
debate (7). It is interesting that the existence of such higher-order complexes has been
demonstrated for some GPCRs (8–10) but not for others (11); thus, the controversy is still
alive (12). Collectively, these findings suggest, however, that our original proposal of high-
order receptor oligomers is correct. In particular, by means of recent fluorescence-based
approaches it has been possible to demonstrate the existence of these structures. Thus, by
combining bimolecular luminescence complementation/bimolecular fluorescence
complementation, respectively and resonance energy transfer (RET)-based approaches (e.g.,
bioluminescence-RET and fluorescence-RET) it has been demonstrated that at least three
adenosine A2A receptors (A2ARs) (13) and four dopamine D2 receptors (D2Rs) (14) are
located in close molecular proximity in living mammalian cells, consistent with their
organization as higher-order oligomers in the plasma membrane. On the other hand, by
using sequential RET approaches it has been possible to demonstrate the existence of
trivalent GPCRs complexes in living cells, for instance the existence of higher-order A2AR-
CB1R-D2R (15) and A2AR-D2R-mGlu5R (16) heteromers has been shown. It is important to
mention here that although this highly ordered organization has been supported by means of
atomic force microscopy observations of native rhodopsin (17–19) the exact stoichiometry
and the specific subcellular localization of these oligomeric structures has not been assessed
yet.
Recently, other set of studies support the existence of higher-order receptor oligomers. In the
case of the β2-adrenergic receptor (β2-AR), the group of Kobilka has demonstrated that the
receptor is predominantly tetrameric following reconstitution into phospholipid vesicles
(20). These authors made also the interesting observation that binding of inverse agonists
leads to significant increases in fluorescence resonance energy transfer (FRET) efficiencies
for most labeling pairs, suggesting that this class of ligand promotes tighter packing of
protomers and/or the formation of more complex oligomers by reducing conformational
fluctuations in individual protomers (20). Overall, our original hypothesis on the existence
of high-order GPCR oligomers is now gaining new important experimental support.
It is obvious that the original hypothesis of high-order GPCR oligomers implies the
existence of multiple receptor interfaces and accordingly it has been experimentally shown
that in the case of D2Rs as well as of other GPCRs (see, e.g., Table 1 in Filozola’s article
(21)) transmembrane domains (TMs) I, IV, and/or V play a role in dimerization/
oligomerization (14,21). As mentioned above, the recent discovery of GPCR dimers/higher-
order oligomers suggests that the selective targeting of these oligomers by specific drugs or
by small molecules that interfere with the receptor–receptor interfaces may provide new
opportunities for novel drug discoveries.
In the present review findings on the A2AR–D2R dimers/higher-order oligomers will be
presented in the context of a careful discussion on the terminology to describe the
phenomena. Finally, comments on possible new strategies on drug development based on
these phenomena will be presented.
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It is worthwhile to introduce by means of operational definitions some basic terms largely
used in the study of protein networks at the plasma membrane level, and hence, also of the
receptor function and the assembly of GPCRs into an integrative center:
Microprocessor is a term introduced by Kenakin (22) to indicate that 7TM receptors are not
just “on-off” switches; rather, they have a high capability to elaborate information. In fact,
by being allosteric proteins and having several intrinsically disordered domains (23) GPCRs
are able to adopt many isoenergetic conformations. This idea is consistent with molecular
dynamics data, which suggest that regions of intrinsic protein disorder are particularly high
in cellular signaling proteins capable of assuming multiple conformations and of taking part
in several protein–protein interactions. In agreement with this capability GPCRs also exist as
clusters of interchanging conformations referred to as ensembles, and ligands produce
changes in these ensembles by selectively binding to preferred conformations. Thus,
stimulation of GPCRs by an agonist leads to a conformational change and to a transition of
the receptor as it switches from an inactive to an active conformation, which can then couple
to its cognate G protein. Conformational changes upon agonist binding have been well
established to proceed through a rearrangement involving TMIII and TMVI (24–28). These
changes are believed to be transmitted into the third intracellular loop. This loop seems to
contain the key domains for coupling to G proteins, particularly in its C terminus (adjacent
to TMVI) but also in its N terminus (adjacent to TMV) regions (29). Although classic theory
assumed that receptors simply switch between “off” and “on” states, more recent data
indicate that agonists of different efficacy might induce different changes in receptor
conformations (30–32). Partial agonists do not induce a smaller proportion of the same
active receptor conformation compared with full agonists but instead evoke ligand-selective
conformations. Thus, a complex picture of receptor activation emerges in which distinct
changes in different regions of a receptor may induce the ability to interact with different
downstream proteins (33).
Colocalization means the simultaneous presence of the proteins under scrutiny in the same
location, usually, within the same subcellular compartment. As far as GPCRs are concerned,
they are colocalized when they are present in one and the same microdomain of the cell
membrane, as, for instance, a membrane lipid-raft. Interestingly, colocalization can be
assessed by means of computer-assisted image analysis of dual-channel fluorescence laser
microscopy images (34) or by applying methods derived from spatial statistics to electron
(35) or to atomic force microscopy images (see, e.g., ref. 36).
Receptor homodimers/heterodimers and higher-order receptor oligomers
This term describes the pairings of receptor in the cell surface forming a functional centre
possibly possessing unique signaling and binding properties. Homodimers are pairs of the
same receptor, whereas heterodimers are formed by different receptors. Each receptor in the
dimer is referred to as a protomer (37). Usually, more than two receptors (or protomers)
associated in an assembly of multimers are considered to form a higher-order receptor
oligomer, which could either be a higher-order homomer or a higher-order heteromer.
Oligomer is defined as any multimeric protein that contains a finite, relatively small, number
of subunits that are not in covalent linkage, but in a state of reversible association with each
other (38). Oligomerization can occur also between GPCRs where the assembly of two or
more than two receptors forms a complex of receptor multimers, which can be detected, for
example, by means of coimmunoprecipitation (39–45). More recently, FRET and
bioluminescence resonance energy transfer (BRET) have been used to detect both receptor-
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receptor interactions (RRIs), and receptor’s conformational changes (32,46–56). As
mentioned above, our group has suggested a completely different way on the basis of a
statistical spatial approach to evaluate the distribution of immunogold particles in images
acquired by means of atomic force microscopy analyzed by means of computer assisted
image analysis (36). This approach is illustrated in Figure 1. It should be noted that all these
techniques are highly indicative of the existence of class A GPCR dimers/higher-order
oligomers, but none demonstrates the existence of these oligomers in living animals (see,
e.g., ref. 57). Thus, the early studies on the functional counterpart of the receptor
oligomerization, namely, the strong indications from binding studies on intramembrane
neuropeptide–monoamine receptor interactions at the level of receptor recognition based on
the existence of allosteric RRIs fully maintain their importance (1,3,5,58).
Allosteric RRIs have been defined as the intramembrane phenomenon by which the affinity
of the orthosteric binding site of receptor B is changed by the binding of a transmitter to the
orthosteric site of receptor A. As already mentioned, indications for RRIs have been
obtained in the 1980s by means of binding experiments of radioactive ligands in membrane
preparations and in brain sections. Number of binding sites and affinities for receptor B (in
the absence and in the presence of the ligand for receptor A) have been evaluated by means
of liquid scintillation counting of radio-labeled receptors and computer-assisted image
analysis of the autoradiographic plates, respectively (see ref. 5). These studies allowed the
demonstration that the ligand for receptor A could modulate the biochemical characteristics
of receptor B. Thus, an activated GPCR could trigger a conformational change of functional
relevance for another receptor in membrane preparations, even in the absence of the
intracellular machinery involving phosphorylation events (for reviews see refs. 59–61). In
the 1980s, correlates of such a molecular mechanism have also been obtained by means of in
vivo studies carried out in physiological and pathological animal models (see refs. 62–64).
Recently, more direct evidence for the existence of a conformational cross talk in receptor
heteromers have been obtained in live cells by using a FRET approach (32).
Cooperativity
The binding of more than one molecule of the same ligand to a multimeric protein. Hence,
cooperativity is manifested when binding of a ligand alters the affinity for subsequent
binding of the same ligand to the other protein subunits via allosteric changes in the contact
zone. In the case of receptors, cooperative binding is the binding of more than one molecule
of the same transmitter to a receptor multimer (65). According to these definitions,
cooperativity is a special case of allosteric interaction (see ref. 66).
Horizontal molecular networks
Proteins embedded and/or associated with the membrane form the so-called horizontal
molecular networks (HMNs) that can also operate as autonomous integrative modules
carrying out specialized tasks (see Figure 2 and refs. 67,68). Furthermore, HMNs consist of
membrane proteins, which can be assembled according to specific topologies, hence forming
“mosaics.” Such mosaics may last longer or for shorter period of times; therefore, it can be
surmised that they undergo a reshuffling, including addition of new proteins (“tesserae” of
the mosaic) or alteration in their topology. A functional and structural relationship exists
between GPCRs and HMNs. As mentioned previously, these receptors, like all proteins, can
adopt numerous tertiary conformations. Thus, they can also interact with cellular proteins,
playing an important role in the formation of HMNs where they can function as
sophisticated signaling-processing centers (69).
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Also receptors, in particular GPCRs, can form mosaics, which may or may not be part of a
HMN. In the first instance, they work as a specialized input unit not only to the vertical
molecular networks (VMNs, i.e., to molecular networks that extend into the cytoplasm and
often reach the nucleus) but also to the HMN itself, allowing a major increase in the
intramembrane elaboration of information (67). The existence of receptor mosaics (RMs) of
different kinds of GPCRs has recently been demonstrated in cell lines (15,16). It should be
noted that a RM being localized at the membrane level may sometimes in itself represent an
isolated HMN. The basic properties of an RM can be deduced from the RRI phenomenon.
As a matter of fact, a RM has been defined as an assembly of receptors with direct physical
interactions between them, which has the following features (23):
• A receptor assembly works as an RM if and only if at least one receptor modulates
via allosteric RRIs the biochemical/functional features of at least another receptor
of the assembly.
• The fluctuations of each receptor (of the RM) among its possible conformational
states are conditioned by the conformations of the other receptors in the mosaic.
Hence, each receptor will respond to its ligand in a way that depends not only on its
own conformation but also on its allosteric interactions with the other receptors of
the macromolecular assembly.
• Given a certain stoichiometry of a RM vs. the dimer condition, the RRIs that take
place obviously depend on the topology of the RM, that is, on the spatial
arrangement of the receptors forming the assembly and on the efficacy of the
“allosteric pathways” interconnecting the receptors with each other (70–72).
As anticipated already in the early studies (4,58), RMs are endowed with “emergent
properties,” that is, with biochemical characteristics and functions that could not be fully
anticipated by analyzing the characteristics of the single participating receptor monomers. In
fact, the effects of oligomerization on the functional features of the monomers can be shown
already at the level of dimers. It may be mentioned that opioid receptor subtypes acquire
new biochemical and functional characteristics when forming heterodimers. Thus, k-δ and
δ-μ opioid receptor heterodimers represent a new receptor entity endowed with new
characteristics with regard to ligand binding and functional properties (e.g., G-protein
coupling) that are distinct from those of the participating monomer receptors (43,73,74). The
same phenomenon has been observed for the D1R-D2R heteromer with a shift from Gs
(D1R) and Gi/o (D2R) to a Gq/11 coupling (75). Thus, we have introduced the concept of
“phenotype-plastic receptors” to indicate the phenomenon in which some monomers after
heterodimerization show a fully different recognition/decoding mechanism when compared
to the single monomers or homodimers (36). In an interesting critical article, the possibility
has been raised that GPCR oligomers of class A are not truely formed but only transient
“kiss-and-run” encounters between the two receptors take place (57) in contrast to class C
GPCRs where covalent bonds develop. Even if several experimental approaches suggest that
long-lasting oligomerization occurs between GPCRs of class A, we have put forward the
hypothesis that the “kiss-and-run” phenomenon could also be of importance in the transient
change of synaptic weight obtained via the assembly of special RMs. It may be possible that
the highly transient assembly (that we called the Casanova-type of RRI) can play a role in
some form of ultra-short memory processes (36). Among these emergent properties it may
be important to mention the following:
• The appearance of new characteristics of the binding sites present in each protomer
or the appearance of entirely new binding sites for extracellular or for intracellular
ligands (e.g., for receptor-interacting proteins like G proteins and β-arrestin).
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• Different localization of the RM with respect to the isolated protomers (e.g.,
preferential localization in the lipid rafts).
• Different turnover rate and desensitization with respect to the isolated protomers.
The scheme of Figure 2 conveys some main features of the terms introduced. The protomers
are single GPCRs that can be in most cases fully functional, that is, capable of recognizing
and decoding an extracellular signal. These protomers can associate into dimers that can also
be fully functional. Protomers and/or dimers can be aggregated to form a RM. It should be
noted that a protomer or a dimer or an RM can also become physically linked to other
extracellular or intracellular proteins forming a HMN. The following nomenclature may be
suggested:
• A first-order microprocessor (for the term microprocessor see ref. 22) gives rise to
an intracellular cascade of the first-order, as it involves a single protomer. In the
case that it interacts with some membrane protein, a first-order HMN is formed.
• A second-order microprocessor gives rise to an intracellular cascade of the second
order, as it involves a dimer. In the case that it interacts with some membrane
protein, a second-order HMN is formed.
• Higher-order microprocessor gives an intracellular cascade of the higher order
when we are dealing with at least a trimer (i.e., an RM). Thus, it should be noted
that only for higher-order microprocessors does topology play a role. In the case
that the higher-order microprocessor interacts with some membrane protein, we
have a higher-order HMN.
It is likely that GPCRs can be inserted in the membrane as protomers or as a dimers or even
as oligomers. However, it is very well possible that oligomers are formed after the insertion
of protomers or dimers at the membrane level and, in some cases, after the action of an
extracellular signal (20).
It should also be noted that GPCRs may or may not belong to a HMN (see previous
discussion). In the former case, they likely represent the hub proteins around which the
HMN is organized. In agreement with this view is the case of the adenosine A1 and A2A
receptors and their interacting proteins (see ref. 76). Crucial aspects not yet clarified in
details concern the mechanisms that control the formation of dimers and higher-order
oligomers, their insertion at membrane level, and in which membrane microdomain, as well
as their participation in HMNs. It may be surmised that the endoplasmic reticulum and
chaperones (i.e., quality control of protein folding and transfer), cytoskeleton, lipid
composition of the membrane, all play a role, but how these mechanisms are interconnected
in a complex control has not yet been clarified. Furthermore, it should also be considered
that all the assemblies formed (dimers, RMs, and HMNs) are potentially plastic oligomeric
structures. Hence, they cannot be internalized simply as such, but they can also be modified
by the addition of new components and/or by disruption from some of the previously
associated components. It is interesting to note that discrete conformations of GPCRs
induced and/or stabilized by specific ligands, even in the absence of receptor
phosphorylation, can promote distinct and functionally specific conformations in receptor-
interacting proteins, for example, in the β-arrestins (77). Thus, β-arrestin can adopt multiple
“active” conformations under the influence of 7TMRs operating as a hub in a VMN. As
stressed by the Lefkowitz’s group their findings demonstrate that functionally specific
receptor conformations can indeed be translated to altered direct coupling to downstream
proteins, in particular to proteins working as effectors such as β-arrestins, thereby governing
their functional specificity (77).
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Another important aspect that is under intense debate is whether the receptor-G protein
complex is constitutively assembled in an inactive state and only becomes activated upon
ligand binding to the receptor (precoupling model), or whether it only forms after agonist
exposure, in which case the receptor-G protein interaction would be diffusion limited, that
is, by free collision coupling (55). It has also been proposed that GPCR–G-protein signaling
does not necessarily require G-protein dissociation. Thus, FRET and BRET studies in intact
cells have led to the conclusion that at least some G proteins can signal in response to
receptors or other stimuli without the need to dissociate (78). These studies can be important
also for another interesting functional aspect, as it can be questioned whether G-proteins are
organized in a chain as the original article by Rodbell (79) and some recent reports suggest
(80). Nevertheless our group has proposed that such an organization could have some formal
analogy with the Turing machine (36) even if it remains to demonstrate whether the G-
protein chain can move in only one direction.
A theoretical comparison between the terms RM and receptor heteromer
The protein oligomerization is of fundamental importance for biochemical processes: it is
sufficient to consider the cooperativity phenomenon, which can occur in multimeric
proteins. To properly underline this aspect It should be mentioned that Monod pointed out
the important biological role played by the “allostery” for protein functions by defining this
phenomenon as “the second secret of life,” as allostery could be considered in importance
second only to the genetic code (81,82). Thus, oligomerization of receptors and possible
allostery including cooperativity in their assembly into oligomers can play a fundamental
role in the recognition/decoding processes of extracellular and synaptic signals impinging on
the cell membrane (36,83). Thus, it is worthwhile to point out some implications of the
multi-facet meaning of the term RM by comparing it with the term high-order heteromers,
introduced by our group (6) simply to indicate the receptor assembly by means of an already
available biochemical term for protein assembly into multimers (see above “Basic
Definitions”).
It is certainly possible to have receptor colocalization without receptor heteromerization and
it is also possible to have receptor heteromerization without allosteric RRIs. Therefore,
receptor assembly where RRIs take place is not simply heteromerization that is a structural
clustering of monomers, but rather a functional construct capable of operating as an
integrative centre. Thus, the term RM has been introduced, as it conveys a feature of the
receptor assembly that can be of a basic importance for its function, namely, the spatial
arrangement of the monomers, that is, the topology of the receptors in the oligomers (see
below). As a matter of fact, the receptor topology, that is, receptor location with respect to
each other, can affect:
• The order of progression of the allosteric RRIs, which can take place only between
receptors that are in contact.
• The possible circulation of the allosteric RRIs within the RM is also dependent on
the allosteric pathways, which are obviously determined by the spatial arrangement
of the receptors and the biochemical characteristics of the receptor–receptor
interfaces, in addition to the affinity and concentrations of the transmitters and
allosteric modulators
• The existence of a “Hub Receptor” (23,67,84,85), that is of a receptor that in view
of the number of its connections with the other receptors of the RM can play a
special role. Obviously, the concept of hub receptor is strictly dependent on the
location of that receptor with respect the other receptors of the mosaic and on the
efficacy of the allosteric pathways of the hub receptor to transmit the allosteric
modulatory signal.
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• The possibility of cooperativity in a RM of homomers (66,86,87) which can simply
be a RM of homodimers coming together. It should be underlined that cooperativity
markedly affects the behaviour of a RM and it has been suggested that positive
cooperativity in a RM of homomers can be an important mechanism to enhance the
capability of a RM located in an extrasynaptic position to detect low concentrations
of the transmitter signal (see refs. 36,83). Negative cooperativity was the one first
described and found to exist in β2-ARs (88,89) and may represent a negative
feedback mechanism at high transmitter concentrations found especially in the
synapse. It should be noted that cooperativity is strongly affected not only by
stoichiometry, but also by topology (see the Appendix).
Thus, due to topology and the rank order of activation it is possible to have markedly
different integrations for RMs formed by the same set of receptors of different kinds (i.e.,
same stoichiometry) and certainly these features are not grasped by the term higher-order
heteromers, a term conveying only the stoichiometry characteristics of the oligomer.
In an interesting recent commentary (7) it has been pointed out that ion channel receptors are
oligomers formed by different nonfunctional subunits and only the complete assembly of
protein subunits forms a functional complex by building up an ion channel. It has been
proposed to use a dichotomy classification by naming “the ion-channel receptors
“heteromeric receptors,” whereas, in view of the fact that each GPCR protomer in a receptor
oligomer is a functional receptor, the complex is called a receptor heteromer (7). This
proposal is a timely and valuable effort to give a logical framework to a rapidly expanding
field, but it has some pitfalls:
• The statement of the functional competence of each GPCR forming the oligomer is
not true for the well-known GABA B R1 and GABA B R2 heterodimer, which is
functionally competent only as a dimer, and, therefore, should be called, according
to the proposed nomenclature, a heteromeric receptor (7). Furthermore, it should
not be overlooked that some “orphan receptors” can operate to make functional
other GPCRs (90) or, at least to modulate their recognition/decoding mechanisms
as shown for the orphan 7TM protein GPR50 when forming a complex with the
melatonin MT1 receptor (91).
• In addition, the symmetrical definition of heteromeric receptors vs. receptor
heteromers has also the fundamental defect of not taking into account the spatial
design of the two types of assemblies. It is well known that the conformation of a
protein determines its function and, similarly, the topological arrangement of
monomers in an assembly determines the geometry of its quaternary structure and
thus its function (92). Thus, in our opinion, it is the topology of receptor monomers
in the oligomer that makes a clear cut dichotomy between the ion-channel receptors
and the GPCR oligomers. As a matter of fact, whereas ion channel receptors have
as topology an obligatory assembly of the subunits around a channel, the receptor
GPCR heteromers can in principle be assembled according to several different
topologies (93).
The possibility of domain-swap models has been proposed, that is, models in which domains
TM1–5 and TM6–7 could exchange between protomers (see ref. 23,94). Although there is
limited direct evidence that supports such models (95), there are also enough data to support
the view that GPCRs exist and function as oligomers. As a matter of fact, this is a reasonable
assumption in view of data carefully reviewed by Filizola (21) supporting the view that
GPCRs exist and function as contact dimers or higher-order oligomers with TM regions at
the interfaces. In contact dimers/oligomers of GPCRs, the original TM helical-bundle
topology of each individual protomer is preserved and interaction interfaces are formed by
lipid-exposed surfaces.
Agnati et al. Page 8













In any case, several authors have proposed on the basis of experimental evidence the
simultaneous involvement of lipid-exposed surfaces of TM1, TM4 and/or TM5 at the
interfaces of assembled GPCR complexes of oligomers (14,39,49). Thus, if more than one
interaction surface exists in a GPCR it is reasonable to assume that several patterns of spatial
arrangements (i.e., topologies) can take place when the GPCR takes part in an oligomer.
Thus, the term oligomerization conveys only part of the information, as it does not take into
account the spatial arrangement of the protomers. It could be stated that the relationships
between oligomerization and topology for a RM are similar to those between “molecular
formula” and “structural formula” of a compound in Chemistry. This analogy has the
relevant consequence that as in Chemistry there can be more than one compound (i.e.,
structural formula) with the same molecular formula the same is true in a receptor oligomer
where there can be more than one mosaic with the same oligomerization (see lower panel of
Figure 3). Thus, the integrative action of a RM targeted by transmitters and allosteric
modulators depends on both stoichiometry and topology. However, in the presence of
multiple interacting surfaces leading to similar (or even identical) topologies the efficacy of
the various interfaces in transmitting the allosteric signal may become especially relevant for
the integrative action of the RM. As a matter of fact, we have pointed out in the past (refs.
87,96; see also refs. 97,98) that proteins can be assembled thanks to their Lego property and
hence with the only restraints being the rules of protein-protein interactions giving rise to
several different topologies (plans according to which monomers are assembled). Even for
trimeric RM, for instance, two different plans of assembly, the linear vs. the triangular one
(see ref. 93), could be hypothesized.
Another aspect that likely has a full meaning only with the GPCR heteromers (90) is the
existence of Hub Receptor, which has been defined as the GPCR that can interact with
multiple partners either receptors or proteins associated with the membrane (see also above
and refs. 23,99).
Summing up, all these considerations underline the importance of the RM term, which
conveys the concept of topology and may have a potentially great impact on the integrative
functions of RMs and hence on the input signals to neurons (83,87,100–102). For a more
penetrating analysis is left the problem of detecting the preferential allosteric pathways in
the oligomer, which as discussed below may affect also cooperativity.
Some implications of the RM concept for the information handling
As pointed out by Milligan (103) a fundamental question is, why are receptors dimers? Or
more generally why is the GPCR oligomerization phenomenon so widespread? Milligan
considers different possibilities such as:
• Facilitation of G-protein activation. This does not seem to be the real reason of
oligomerization, as the GPCR dimerization does not appear to be a general
requirement for intracellular signal generation (see also ref. 57). As a matter of fact,
the likely functional competence of single GPCR monomers has been demonstrated
(14). Thus, both rhodopsin (104) and the β2AR) (105) have been shown to signal
efficiently to G proteins when reconstituted into lipid nanodiscs containing only a
single receptor. Thus, after solubilization and reconstitution, these GPCRs can
function on their own.
• Control of membrane surface delivery. Milligan and Bouvier discuss studies that
appear to provide strong support for the concept that GPCRs traffic to the cell
surface as dimers or higher-order oligomers and only after passing ER/Golgi export
quality control. Thus, this can be an important regulatory mechanism of GPCR
turnover involving oligomerization (103,106,107)
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Lohse has also made the interesting suggestion that among the possible functional effects of
receptor dimerization a cross regulation in cell surface mobility should be considered (52).
This aspect has been indicated in the scheme of Figure 2. where also the preferential
targeting to membrane microdomains with a special composition of protomer vs. dimers and
RMs is indicated.
Our group has put forward some other fundamental reasons (36,60,87,99) that can be
summarized as follows:
• Combinatorial property of high relevance for learning and memory that is acquired
by means of the different assembly of receptors (tesserae) in a mosaic not only
taking advantage of different stoichiometry, but also of different topologies with
the same stoichiometry. Thus, with the same set of receptors (tesserae of the
mosaic) it is possible to obtain markedly different topologies and hence likely
different integrative functions of the RM (Figure 3). This can be viewed as a
“tinkering process” (108) that has high relevance in biochemistry as demonstrated
by considering that, for example, the genome is basically built by only four
nucleotides and proteins by 20 amino acids.
• The possibility to have a preliminary elaboration of the information already at
membrane level. This elaboration could either filter the relevant signals that in fact
reach the VMNs and/or give integrated signals to these molecular networks and to
the HMNs. A very interesting case of such a filtering process is the one discovered
by Vilargada, Lohse and Collaborators of a direct transinhibition by MOR of α2A–
AR that can also help explain previously described antagonistic NPYR-alpha2
RRIs at the membrane level (see ref. 99). Thus, morphine binding to the MOR
triggers a conformational change in the norepinephrine-occupied α2-AR that
inhibits its signaling to Gi and the downstream MAP kinase cascade. It has been
assessed that the cross-conformational switch that permits direct inhibition of one
receptor by the other in the heteromer occurs with sub-second kinetics. In other
words, the allosteric signal propagates over the receptor interface to induce its
conformational changes, which are of high functional relevance (ref. 32; see also
refs. 64,99).
• To have negative or positive cooperativity in homomers with a great spectrum of
different strengths (83). Let us illustrate this point further by considering a special
case, for example, of a tetramer formed by the same homodimer or two different
types of homodimers. A tetramer can be surmised similar to that of hemoglobin
(two α and two β subunits) binding the same ligand or a tetramer in which one
dimer binds a ligand and the other dimer binds another ligand. This speculative
example is only to give a hint of the extraordinary spectrum of possibilities of a
biochemical high-order microprocessor formed by only four elements. In addition,
it is also possible to surmise that a quadrangular topology has a completely
different behaviour from a linear topology (see the Appendix).
• RRIs and more generally HMNs can play a role in enabling functional capabilities
of certain membrane microdomains (109). In fact, it has been considered that
particularly lipid rafts via protein–lipid interactions can play a role in favoring the
localization of certain RMs and, more generally, the formation of specialized
HMNs in these rafts but heteromerization can occur independently of lipid rafts
(48,96). A similar proposal has been put forward by Maggio and Collaborators
(110) by suggesting that protein–protein as well as protein–lipid interactions may
provide the structural basis for organizing distinct cell compartments along the
plasma membrane where different extracellular signals may be perceived and
discriminated.
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• It has been also proposed that RMs especially in association with HMNs can play
an important role in the modulation of the “synaptic weight” and thus in the process
of learning and memory (100). Thus, a learning model that can take into account
not only the connections between the cells, forming cellular networks able to adapt
their function according to the stimuli they receive, but also molecular networks
especially RMs and associated HMNs has been proposed. According to such a
proposal, memory formation seems not only to be a distributed process, but also to
follow a hierarchical morpho-functional organization (111).
Possible implications of the RM concept for new strategies in drug
development
As discussed above, GPCR heterodimers can generate very distinct signals apart from the
corresponding homodimers. The development of small-molecule ligands that are specific for
these complexes is a potential new way to discover novel drugs with higher selectivity of
action. Thus, one can surmise alternative approaches as schematically depicted in Figure 4.
by developing the so called “bivalent ligands” and other drugs selective for a certain dimer
or for a certain heterodimer (7, 21,102).
The interesting Filizola’s perspective does not take into account an important feature of the
GPCRs, namely, the possibility of a modulatory action on the orthosteric binding site via an
allosteric modulator acting on the same receptor or on another receptor of the receptor
heteromer (see refs. 112,113). In fact, as clearly stated by Kenakin (69,114) there is an
increasing prevalence of allosteric ligands as investigational drugs. Although allosterism
traditionally has been discussed in terms of affinity changes of receptors, the increasing use
of functional pharmacological assays makes it mandatory to consider effects on both affinity
and efficacy. Antagonism of agonist response can occur allosterically by reduction of
affinity and/or efficacy but the antagonism will have different properties depending on
which of these is primarily affected. It is clear that antagonism can be achieved by either
blocking affinity but not efficacy, reducing efficacy but not affinity, or both (115).
Because an allosteric modulator allows agonist binding to the receptor, there can be
differences in the resulting effect and allosterically-induced texture in antagonism can lead
to other interesting properties. GPCRs are allosteric systems that have a modulator (ligand
or protein) that interacts and transmits information through a conduit (receptor) to a guest
(either other ligand, interacting protein or cytosolic protein). Thus, such receptor allostery
can be discussed as vectorial transfers of information from ligand-binding domains
(“classical” modulator allosterism) to the cytosol (functional selectivity) and along the plane
of the membrane (receptor oligomerization) (37).
Thus, Kenakin notes that there are at least three advantages to use allosteric modulators for
cell-surface receptors:
1. they are saturable and therefore there is a ceiling to the effects of a drug;
2. allosteric ligands have the ability to selectively fine-tune responses at receptors
upon activation of the orthosteric sites in specific tissues;
3. allosteric drugs have the potential for greater receptor subtype selectivity, as the
receptor subtypes are activated by the same transmitter.
It can be added that usually an allosteric modulator maintains the temporal code by which
the endogenous orthosteric ligand acts on the target cell at any receptor illustrated in the
three panels of Figure 4. It is possible to add the allosteric modulation of the orthosteric
binding site with possible secondary effects on the orthosteric binding site of other receptors
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of the oligomer or on the heterodimer orthosteric binding sites as depicted in Figure 5. It
should also be considered the development of drugs affecting not the orthosteric binding
sites nor the formation and the maintenance of the oligomer (see ref. 21), but simply the
transmission of allosteric signals along the amino acid pathways connecting binding sites of
the oligomer. Thus, we have postulated the possible development of drugs acting on the
“check points” localized along these pathways (36).
It is, therefore, clear that the RRI phenomenon has opened up a new field not only for a
better understanding of the molecular mechanisms of recognition/decoding of the
extracellular and synaptic signals and hence of the information handling by neural networks,
but also of new strategies for drug development. A brief discussion of some aspects related
to these new strategies for drug development has been previously presented by our group
(102,116).
In conclusion, as we have already discussed, the early studies on RRIs carried out in the
1980s were fully aware of the potential importance of this molecular phenomenon and
focused specifically on the molecular integration of signals, in order to achieve a better
understanding of brain’s functions. We and others have also suggested that an alteration in
specific RRIs could play a role in pathogenic mechanisms leading to several diseases inter
alia Parkinson’s disease, hypertension, schizophrenia, addiction, and depression (102,117–
122). Thus, it is only logical to propose that pharmacological targeting of RRIs could
represent an important area to develop more selective drugs, including bivalent compounds
and optimal types of combined treatments (see above and also refs. 7,73,123–126).
All the strategies listed in Figure 4 are important. However, it should be considered that
there will always be a place for treatments based on the coadministration of drugs acting on
different GPCRs even if these receptors form an heterodimer or a RM. Therefore, in our
opinion, it could be important in many cases to either study each of them separately, on a
case-by-case basis, or embark on a combined study, clubbing two or three cases together;
thus, it would help protomers to take advantage of the different pharmacodynamics and/or
pharmacokinetics of the coadministered drugs, which may more optimally target their
respective receptor than bivalent drugs.
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APPENDIX: Theoretical ligand binding curves
As illustrated in Figure 3, a cluster of receptors can in principle be arranged in different
ways, depending on the physical constraints of the membrane environment in which the
subunits are placed and on the interaction interfaces available to them.
To analyze the influence of the geometrical arrangement on the properties of the receptor
clusters, theoretical ligand binding curves will be here derived for the different arrangements
available to a trimeric receptor mosaic of identical subunits.
The analysis will be performed in the framework of the well-known Koshland–Nemethy–
Filmer (KNF) model (127), based on a sequential scheme for the binding to a multisubunit
protein:
For each binding step we have an equilibrium condition of the form (see (128)):
(1)
Where L denotes the ligand, Ri the protein complex with i occupied sites and ΔG0 is the
change in free energy involved in the transition. The multiplicity factor ni accounts for the
number of ways to achieve i occupied sites.
According to the KNF model, ligand binding at one subunit is assumed to cause a local
conformational change (“induced fit”) leading to conformational changes at nearby subunits,
affecting their affinity for the ligand. Thus, for each binding step the change in free energy
at the equilibrium will depend on three energetic factors: the binding energy, the intrinsic
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energy difference associated with the conformational change of a subunit and the subunit-
subunit interaction energy. To simplify things, however, it was also assumed that the
conformational transition of each subunit is concomitant with ligand binding. As a
consequence each subunit can be considered to have only two possible configurations (F or
“free” and B or “bound”) and the contributions due to ligand binding and conformational
change can be lumped together taking the energy per binding event as the free energy
difference per subunit between the completely free and completely occupied states.
Considering as G0=0 the free energy of the completely unoccupied receptor cluster, we can
denote the free energy change associated with the binding of a ligand as:
(2a)
Where KL is a binding constant including not only the energies directly relating to protein-
ligand interactions, but also the energy of the obligatory conformational transition.
As far as the subunit-subunit interactions are concerned, they can be similarly denoted as:
(2b)
(2c)
Where KFB and KBB express the interaction energy between F-B and B-B pairs of interfaced
subunits respectively.
Thus, for a state with i occupied sites, j F-B and z B-B interfaces between subunits, the free
energy change relative to the completely unoccupied state is:
(3)
The different states available to a trimer arranged according to a linear or triangular
topology are illustrated in Figure 6 together with the corresponding values of the parameters
n, i, j, z.
Thus, with a ligand concentration of L, by using the equations (1) and (3) the equilibrium
between a trimer with zero and one occupied site can be espressed as:
And the concentration at equilibrium of single bound trimers (i.e., R1) will be:
(4a)
Agnati et al. Page 20














R2 and R3 can be obtained following the same approach by using the corresponding data





Being the fraction of occupied binding sites:




representing the saturation curves of the trimer in the two configurations.
It is noteworthy that with zero interaction energy, according to equations (2b) and (2c) we
have KFB=KBB=1 and both (7a) and (7b) become:
This is what one would expect for a cluster of completely independent subunits (Michaelis-
Menten curve).
When subunit-subunit interactions are established, however, (7a) and (7b) define
substantially different saturation curves as illustrated in Figure 7A, indicating that the
existence of receptor–receptor interactions lead to a significant dependence of the receptor
cluster response on the geometrical arrangement of the subunits within the cluster. In
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particular, on comparing the curves obtained with identical values for the constants, it can be
seen that the steepness of the curve increases and the mid-point shifts as the number of
interactions increases.
The analysis of the tetramer further confirms this point. Three arrangements will be here
considered for a cluster of four identical subunits: linear (in which the two interior subunits
interact with each of the two neighbours, whereas the two terminal subunits interact with
only one neighbour), square (in which the subunit are in a square pattern in which no
interactions across the diagonal occur) and tetrahedral (in which each subunit interact with
the other three). They are shown in Figure 7B together with their saturation curves,
corresponding to the following equations as reported by Leskovac ((129); see also (130)):
for the linear, square and tetrahedral arrangements respectively.
Thus, not only the stoichiometry of a receptor cluster (i.e., the number of component
subunits), but also its topological arrangement (in particular the topological organization of
the interactions between subunits) determines its behaviour. Stoichiometry and topology
should, therefore, be considered as different and complementary characteristics of a receptor
cluster, both significantly influencing its response to an incoming ligand.
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Evaluations by means of spatial statistical analysis of atomic force microscopy images of
HA-tagged A2A and D2 receptor distributions in CHO cell membranes. (A) Experimental
procedure: CHO cells were cultured as described in previous articles (see, e.g., ref. 130).
CHO cells were stably transfected with the human dopamine D2L (long form) receptor
cDNA (2600 kb cDNA fragment cloned into the Plxsn-vector, which confers resistance to
geneticin), and the clones resistant to geneticin were selected (for further details, see ref.
131). As far as the immunogold staining is concerned, cells were grown on glass slides
(Chamber Slide Culture, Labtek = Nunc, VWR International srl, Milano, Italy) coated with
poly-L-lysine (Sigma, Milano, Italy). Cells were then rinsed in PBS, fixed in 4%
paraformaldehyde and glutaraldehyde 2% for 20 min and washed with PBS containing 20
mM glycine and subsequently treated with PBS = 20 mM glycine = 1% BSA for 30 min at
room temperature. Immunostaining was performed with the affinity purified mouse anti-HA
antibody (Roche SpA, Milano, Italy) and rabbit anti-D2 antibody in PBS, pH 7.4,
supplemented with 1% normal serum at 48°C overnight. The cells were then rinsed three
times for 10 min in Tris pH 7.4, three times for 5 min in Tris pH 7.4 BSA 0.2%, one time for
15 min in Tris pH 8.2 BSA 1% and incubated with 15 nm gold particles-conjugated anti-
mouse (1:25) and 25 nm gold particles-conjugated anti-rabbit antibody in Tris pH 8.2, BSA
1% for 1 h at room temperature. Cells were then rinsed twice for 10 min in Tris pH 7.4. (B)
Atomic force microscopy procedure: images were acquired in tapping-mode (radius of
curvature of the probe tip: 10 nm; frequency: 120–130 kHz; AFM, PARK Autoprobe CP
instrument) to obtain a phase image of a 2 × 2 μm area of the cell membrane (upper panel).
Image analysis was performed according to Agnati et al. (36) and the binary images of the
most probable 15 nm (labeling A2A receptors) and 25 nm (labeling D2 receptors) gold
particles were obtained (lower panel). (C) Spatial statistical analysis: from the x, y-
coordinates of the gravity centres of the 15 and 25 nm gold particles the cumulative
distributions (K(d)) of the distances of each particle from its nearest neighbour of the same
type or of the other type was obtained. Distances were normalized in order to account for the
finite grain size. Thus, a distance of 0 means that two gold particles are adjacent. A number
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of random (Poisson) bivariate point patterns of the same size was also generated in order to
evaluate the distributions in conditions of complete spatial randomness (i.e., K0(d)) and the
95% confidence envelope around it. If L(d) = K(d) − K0(d) is significantly greater than 0 for
any range of d, then particles are colocalized, that is, they are closer to each other than could
be expected by chance (35,132). As illustrated in a range around 10 nm significant A2A–
A2A, D2–D2, and A2A–D2 associations can be detected.
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Schematic representation of a horizontal molecular network (HMN), which by elaborating
the extracellular fluid signals and the cytosolic signals can work as an “intelligent interface”
between the two environments.
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Relevance of the topology for the possible assembly of different receptor mosaics, which
have the same stoichiometry. It is likely that in several instances these stoichiometrically
identical, but topologically different mosaics can be endowed with different functional
characteristics. The lower panel shows two possible topological arrangements of D2, which
are based on the demonstration that both TM1 and TM4 can be involved in the
oligomerization process via a symmetrical TM1-TM1 and TM4-TM4 interactions (14).
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Schematic representation of new strategies for drug development on the basis of the
existence of GPCR oligomerization and especially receptor mosaics. For further details, see
text.
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Schematic representation of a possible new strategy for drug development on the basis of the
existence of allosteric modulators of GPCRs. It should be considered to combine the
allosteric modulation of a GPCR with some of the drugs indicated in Figure 4. In the scheme
of the figure is illustrated an allosteric modulator that by binding to GPCR-A modulates the
heterodimer in such a way to enhance the affinity for the heterodimer ligand. For further
details, see text.
Agnati et al. Page 28














Possible states available to a trimer arranged according to a linear or a triangular structure.
Circles indicate subunits and pairs of interacting subunit are connected by a line segment.
Black circles represent subunits in the “bound” configuration. The parameters (see text for a
definition) i, n, j, and z characterizing each possible state are indicated.
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Examples of saturation curves having the binding and interaction constants indicated and
comparing the various interaction geometries (schematically shown at the bottom) of a
trimer (A) and a tetramer (B). As illustrated, although the curves were characterized by the
same set of constants, they showed a clear-cut dependence on the way the receptor cluster
was arranged.
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